The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease

Urmia University of Medical Sciences

Status: Unknown

Conditions: Non Alcoholic Fatty Liver Disease

Treatments: Dietary Supplement: β- glucan; Dietary Supplement: Maltodextrin

Study type: Interventional

Funder types: Other

Identifiers

NCT02178839

umsu.rec.1393.48

Details and patient eligibility

About

The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with Hypocaloric Diet and Vitamin E.

Enrollment: 48 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Non Alcoholic Fatty Liver Disease From Both Sex
• Age 18-55 years
• BMI more than 25 Kg/m2

Exclusion criteria

• Alcohol Consumption
• Pregnancy or lactation or menopause
• Being a professional athlete
• A history of cancer
• Risk of high blood pressure (in the case of drug use)
• Heart disease - cardiovascular, pulmonary, renal and diabetes
• Liver transplantation and other chronic or acute Liver diseases such as hepatitis B, C and liver infections
• The History of inherited disorders affecting the liver
• A history of autoimmune disease
• History of food allergies
• Taking certain medications such as blood pressure control, statins, insulin sensitivity enhancers and hepatotoxic drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

48 participants in 2 patient groups, including a placebo group

β- glucan

Experimental group

Description:

8.5 g/d of Oat Supplement Containing 3g β- glucan

Treatment:

Dietary Supplement: β- glucan

Maltodextrin

Placebo Comparator group

Description:

8.5 g/d Maltodextrin

Treatment:

Dietary Supplement: Maltodextrin